AI enters selected drug-discovery and clinical-documentation workflows
AI has entered selected drug-development and clinical-documentation workflows, with early trial and adoption evidence; effects remain asset-, tool-, task- and setting-specific and require human oversight.
Also known as: AI drug discovery · clinical AI
Data as of 22 July 2026 (America/Toronto)
Four decision scores
Adjudicated from two independent scorers. Ordinal 1–5, shown separately by design — the research refuses composite rankings.
medium confidence
medium confidence
low confidence
medium confidence
Wealth-management materiality
Qualitative rating across the 11 value-chain functions: High / Medium / Low / Remote-conditional.
- Clients and demographicsL
- Advice and financial planningL
- Investments and portfolio constructionM
- Products and propositionsM
- Distribution and engagementL
- Advisers and workforceM
- Operating modelM
- Technology, data and architectureM
- Economics and business modelM
- Risk, regulation, fiduciary duty and trustM
- Competition, winners and losersM
H High · M Medium · L Low · R Remote/conditional — rationale for each rating is in the full report.
Where it bites hardest
High-magnitude sectors (4)
- technology
- healthcare
- industrials/manufacturing
- public sector
Material geographies (2 of 12)
- United States and Canada
- Mainland China and Hong Kong
Build the full picture for your own sector and geography in My Exposure Map.
In the full report
Full trend profileIn the report
Structural drivers (4), counterforces (5), 2030 outlook, baseline, and regional nuance — the complete evidence-based narrative.
Leading indicators & inflection pointsIn the report
5 monitoring indicators and 6 documented inflection points with trigger conditions.
Evidence chain & citationsIn the report
27 hash-frozen evidence records with verified sources, claim classification, and transmission mechanisms.
Score dissent & adjudication trailIn the report
Both independent scorers' original ratings, the spread, the decision rule applied, and preserved dissent for every score above.
90-day action plan & staged roadmapIn the report
Role-specific actions with owners, thresholds, and milestones from the first 90 days through 2030.
Scenario exposureIn the report
How this trend behaves across the four integrated 2030 scenarios, with stress-test results and early-warning indicators.
The full 1,927-page report contains the complete profile, evidence base, and 90-day action plan for each trend.